Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ALEC Stock Forecast 2026-2027
$1.50
Current Price
$166.54M
Market Cap
Buy 3
Hold 2
Sell 2
Wall St Analyst Ratings
Distance to ALEC Price Targets
+300.0%
To High Target of $6.00
+33.3%
To Median Target of $2.00
-33.3%
To Low Target of $1.00
ALEC Price Momentum
-6.8%
1 Week Change
-14.3%
1 Month Change
-5.7%
1 Year Change
-3.8%
Year-to-Date Change
-55.9%
From 52W High of $3.40
+37.6%
From 52W Low of $1.09
📊 TOP ANALYST CALLS
Did ALEC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Alector is one of their latest high-conviction picks.
Latest ALEC Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, ALEC has a neutral consensus with a median price target of $2.00 (ranging from $1.00 to $6.00). The overall analyst rating is Buy (6.9/10). Currently trading at $1.50, the median forecast implies a 33.3% upside. This outlook is supported by 3 Buy, 2 Hold, and 2 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALEC Analyst Ratings
3
Buy
2
Hold
2
Sell
ALEC Price Target Range
Low
$1.00
Average
$2.00
High
$6.00
Current: $1.50
Latest ALEC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALEC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 15, 2026 | Cantor Fitzgerald | Pete Stavropoulos | Overweight | Upgrade | $N/A |
| Mar 10, 2026 | BTIG | Buy | Upgrade | $N/A | |
| Oct 22, 2025 | TD Cowen | Hold | Downgrade | $N/A | |
| Oct 22, 2025 | Cantor Fitzgerald | Neutral | Downgrade | $N/A | |
| Oct 22, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 22, 2025 | William Blair | Market Perform | Downgrade | $N/A | |
| Oct 22, 2025 | BTIG | Neutral | Downgrade | $N/A | |
| Sep 25, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Jul 28, 2025 | Mizuho | Outperform | Upgrade | $N/A | |
| May 9, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 7, 2025 | Morgan Stanley | Sean Laaman | Underweight | Assumes | $1.50 |
| Feb 27, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 16, 2024 | Stifel | Hold | Downgrade | $N/A | |
| Nov 26, 2024 | Morgan Stanley | Underweight | Downgrade | $N/A | |
| Nov 26, 2024 | BTIG | Buy | Maintains | $N/A | |
| Nov 26, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Nov 7, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 17, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Sep 9, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Jul 29, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A |
Alector Inc. (ALEC) Competitors
The following stocks are similar to Alector based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Alector Inc. (ALEC) Financial Data
Alector Inc. has a market capitalization of $166.54M with a P/E ratio of -1.1x. The company generates $18.42M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -71.5% quarter-over-quarter, while maintaining an operating margin of -2,382.3% and return on equity of -238.9%.
Valuation Metrics
Market Cap
$166.54M
Enterprise Value
$-5,429,219
P/E Ratio
-1.1x
PEG Ratio
0.0x
Price/Sales
8.9x
Growth & Margins
Revenue Growth (YoY)
-71.5%
Gross Margin
N/A
Operating Margin
-2,382.3%
Net Margin
0.0%
EPS Growth
-71.5%
Financial Health
Cash/Price Ratio
+124.0%
Current Ratio
5.3x
Debt/Equity
332.8x
ROE
-238.9%
ROA
-25.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Alector Inc. (ALEC) Business Model
About Alector Inc.
What They Do
Develops therapies for neurodegenerative diseases.
Business Model
Alector Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies to treat neurodegenerative diseases. The company generates revenue through partnerships, research grants, and potential future sales of its therapeutic candidates once they receive regulatory approval.
Additional Information
Founded in 2013 and based in South San Francisco, Alector utilizes human genetics, neuroscience, and immunology to drive its research. Its key programs include a monoclonal antibody for frontotemporal dementia and an antibody targeting Alzheimer's disease, among others. The proprietary Alector Brain Carrier technology enhances the delivery of these therapies across the blood-brain barrier, addressing significant gaps in the treatment of neurodegenerative disorders.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
103
CEO
Dr. Arnon Rosenthal Ph.D.
Country
United States
IPO Year
2019
Website
www.alector.comAlector Inc. (ALEC) Latest News & Analysis
Latest News
Quick Summary
Alector announced that GSK has terminated their neuroscience collaboration for two experimental antibody drugs due to clinical setbacks.
Why It Matters
GSK's termination of the collaboration with Alector signals a loss of potential revenue and progress for Alector, impacting its stock value and investor confidence in its pipeline.
Source: Reuters
Market Sentiment:
Negative
Quick Summary
Alector is advancing its ABC platform with multiple therapies, including antibodies for Alzheimer's, enzyme replacement for Parkinson's, and Tau siRNA for Alzheimer's and tauopathies.
Why It Matters
Progress in Alector's ABC platform signals potential breakthroughs in treating Alzheimer's and Parkinson's, impacting biotech valuations and investor sentiment in related sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Alector (ALEC) is unlikely to meet earnings expectations in its upcoming report due to lacking key performance indicators. Investors should prepare accordingly.
Why It Matters
Alector's lack of key ingredients for an earnings beat may signal weaker performance ahead, potentially impacting stock prices and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Alector (ALEC) reported a quarterly loss of $0.21 per share, better than the estimated loss of $0.35, and an improvement from a loss of $0.41 per share a year prior.
Why It Matters
Alector's narrower quarterly loss than expected may signal improving financial health, potentially boosting investor confidence and affecting stock performance positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Alector, Inc. will discontinue its Phase 2 PROGRESS-AD trial for nivisnebart due to the Independent Data Monitoring Committee's conclusion that it is unlikely to meet its primary endpoint. The company will continue to advance its pipeline for neurodegenerative diseases.
Why It Matters
The discontinuation of Alector's trial signals setbacks in Alzheimer's research, impacting investor confidence and stock performance. Focus shifts to other pipeline candidates, affecting future valuations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Alector, Inc. (ALEC) shows potential as a stock pick after a "golden cross" event, with its 50-day moving average surpassing the 200-day moving average, indicating positive technical momentum.
Why It Matters
Alector's "golden cross" signals potential bullish momentum, indicating a favorable technical outlook that may attract investors seeking growth opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About ALEC Stock
What is Alector Inc.'s (ALEC) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Alector Inc. (ALEC) has a median price target of $2.00. The highest price target is $6.00 and the lowest is $1.00.
Is ALEC stock a good investment in 2027?
According to current analyst ratings, ALEC has 3 Buy ratings, 2 Hold ratings, and 2 Sell ratings. The stock is currently trading at $1.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALEC stock?
Wall Street analysts predict ALEC stock could reach $2.00 in the next 12 months. This represents a 33.3% increase from the current price of $1.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Alector Inc.'s business model?
Alector Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies to treat neurodegenerative diseases. The company generates revenue through partnerships, research grants, and potential future sales of its therapeutic candidates once they receive regulatory approval.
What is the highest forecasted price for ALEC Alector Inc.?
The highest price target for ALEC is $6.00 from at , which represents a 300.0% increase from the current price of $1.50.
What is the lowest forecasted price for ALEC Alector Inc.?
The lowest price target for ALEC is $1.00 from at , which represents a -33.3% decrease from the current price of $1.50.
What is the overall ALEC consensus from analysts for Alector Inc.?
The overall analyst consensus for ALEC is neutral. Out of 3 Wall Street analysts, 3 rate it as Buy, 2 as Hold, and 2 as Sell, with a median price target of $2.00.
How accurate are ALEC stock price projections?
Stock price projections, including those for Alector Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 7:26 PM UTC